Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

920 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients.
van Eijndhoven MA, Zijlstra JM, Groenewegen NJ, Drees EE, van Niele S, Baglio SR, Koppers-Lalic D, van der Voorn H, Libregts SF, Wauben MH, de Menezes RX, van Weering JR, Nieuwland R, Visser L, van den Berg A, de Jong D, Pegtel DM. van Eijndhoven MA, et al. Among authors: de menezes rx, de jong d. JCI Insight. 2016 Nov 17;1(19):e89631. doi: 10.1172/jci.insight.89631. JCI Insight. 2016. PMID: 27882350 Free PMC article.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: de jong d. Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7. Lancet Oncol. 2019. PMID: 30630772 Clinical Trial.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Among authors: de jong d. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ. Chamuleau MED, et al. Among authors: de jongh e, de jong d. Haematologica. 2020 Dec 1;105(12):2805-2812. doi: 10.3324/haematol.2019.238162. Haematologica. 2020. PMID: 33256379 Free PMC article. Clinical Trial.
Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma.
Drees EEE, Roemer MGM, Groenewegen NJ, Perez-Boza J, van Eijndhoven MAJ, Prins LI, Verkuijlen SAWM, Tran XM, Driessen J, Zwezerijnen GJC, Stathi P, Mol K, Karregat JJJP, Kalantidou A, Vallés-Martí A, Molenaar TJ, Aparicio-Puerta E, van Dijk E, Ylstra B, Groothuis-Oudshoorn CGM, Hackenberg M, de Jong D, Zijlstra JM, Pegtel DM. Drees EEE, et al. Among authors: de jong d. J Extracell Vesicles. 2021 Jul;10(9):e12121. doi: 10.1002/jev2.12121. Epub 2021 Jul 15. J Extracell Vesicles. 2021. PMID: 34295456 Free PMC article.
PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach.
Beagan JJ, Drees EEE, Stathi P, Eijk PP, Meulenbroeks L, Kessler F, Middeldorp JM, Pegtel DM, Zijlstra JM, Sie D, Heideman DAM, Thunnissen E, Smit L, de Jong D, Mouliere F, Ylstra B, Roemer MGM, van Dijk E. Beagan JJ, et al. Among authors: de jong d. J Mol Diagn. 2021 Nov;23(11):1553-1563. doi: 10.1016/j.jmoldx.2021.08.008. Epub 2021 Aug 26. J Mol Diagn. 2021. PMID: 34454114 Free article.
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018.
Durmaz M, Visser O, Posthuma EFM, Brouwer RE, Issa DE, de Jong D, Lam KH, Blijlevens NMA, Zijlstra JM, Chamuleau MED, Lugtenburg PJ, Kersten MJ, Dinmohamed AG. Durmaz M, et al. Among authors: de jong d. Blood Cancer J. 2022 Mar 9;12(3):38. doi: 10.1038/s41408-022-00637-1. Blood Cancer J. 2022. PMID: 35264598 Free PMC article.
Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma.
Plaça JR, Diepstra A, Los T, Mendeville M, Seitz A, Lugtenburg PJ, Zijlstra J, Lam K, da Silva WA Jr, Ylstra B, de Jong D, van den Berg A, Nijland M. Plaça JR, et al. Among authors: de jong d. Cancers (Basel). 2022 Mar 5;14(5):1346. doi: 10.3390/cancers14051346. Cancers (Basel). 2022. PMID: 35267654 Free PMC article.
920 results